Table 3 Vedolizumab therapy in 12 patients with IBD
ID | Dosage in mg | Duration of therapy at last follow up, weeks | Response and outcome of therapy |
|---|---|---|---|
CD01 | 250 | 36 | Loss of response, discontinuation in week 37 |
CD02 | 300 | 64 | No remission achieved, dosing interval 4 weeks, variable disease course, therapy ongoing |
CD03 | 300 | 64 | Remission after 14 weeks, variable disease course, therapy ongoing |
CD04 | 300 | 36 | Partial remission in week 14, loss of response, discontinuation in week 34 |
CD05 | 300 | 60 | No remission achieved, variable disease course, therapy ongoing |
CD06 | 200 | 16 | Primary non-responder, discontinuation in week 22 |
CD07 | 300 | 8 | Systemic allergic reaction at 2nd infusion, discontinuation |
UC08 | 250 | 88 | No remission achieved, variable disease course, therapy ongoing |
UC09 | 150 | 96 | Good response, remission, therapy ongoing |
UC10 | 300 | 64 | Total colectomy due to severe course of the disease 60 weeks after vedolizumab start |
UC11 | 300 | 52 | Good response, remission, therapy ongoing |
IBD-U12 | 300 | 52 | No remission achieved, variable disease course, therapy ongoing |